Telix Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TLPPF | NRIX | LGND | IDYA | INBX | AKTS | |
|---|---|---|---|---|---|---|
| Market cap | 3.04B | 1.74B | 6.32B | 3.12B | 1.28B | 845.42M |
| P/E (TTM) | 89.5 | 6.6 | 127.0 | — | — | — |
| Forward P/E | — | -12.5 | 25.9 | -7.9 | -9.9 | -7.1 |
| Price/book | 6.2 | 1.8 | 6.6 | 2.9 | -24.1 | 1.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −5.69% | +27.40% | +51.82% | +8.41% | +7.12% | −32.14% |
| Today | 0.00% | −38.23% | +0.83% | +3.29% | +7.01% | +1.74% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TLPPF news ›Pro Medicus vs Telix Pharmaceuticals: Which is more likely to double your money in 2 years?
Can Pro Medicus or Telix Pharmaceuticals double your money on the ASX? We stack up their value, growth, and price momentum for 2026. Laura Stewart is a Finance Editor at The Motley Fool, where she covers Australian and international equity…
Buy, hold, sell: Telix Pharmaceuticals, BHP, CBA shares
James Bills from Shaw and Partners shares his views and ratings on 3 ASX stocks. ASX shares and ETFs News writing Macroeconomic trends Real estate Diploma in Journalism, Macleay College "Don't look for the needle in the haystack. Just buy…
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans Profound’s…
More from 1 other outlet
Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case
Telix Pharmaceuticals maintains a Buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition. Read more on TLX stock here. - Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the…
Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances
Telix Pharmaceuticals' Q3 2026 update sees strong revenue growth, FDA milestones, and a major merger to expand its radiopharmaceuticals platform. The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today following the…
Telix Pharmaceuticals Shares Slide 6.6% as Radiopharmaceutical Stock Extends Volatile 2026 Run on the ASX
SYDNEY — Shares of Telix Pharmaceuticals Ltd. fell more than 6% on Wednesday, extending a volatile stretch for the Melbourne-based radiopharmaceutical company. Telix shares dropped 1.04 Australian dollars, or 6.60%, to A$14.72 in afternoon…
Telix Pharmaceuticals Limited Stock 12‑Month Price Target Cut to $17.95, Implies 61% Upside
TradingView Telix Pharmaceuticals Limited Stock 12‑Month Price Target Cut to $17.95, Implies 61% Upside - According to estimates from 12 analysts, Telix Pharmaceuticals Limited stock's average price target h
Telix Pharmaceuticals shares slump despite Q3 revenue growth
The news: Shares in Telix Pharmaceuticals tumbled in morning trade despite the global biopharmaceutical company reporting a 19% year-on-year increase in third quarter group revenue to USD245 million ($349 million). Shares slumped 7.3% to…
Telix Pharmaceuticals Limited (TLX) Q3 Update, FDA Pixclara OK, ITM Merger Announced
TradingView Telix Pharmaceuticals Limited (TLX) Q3 Update, FDA Pixclara OK, ITM Merger Announced Telix reported Q3 2026 performance, cited strong U.S. dose volumes, reaffirmed outlook for over 25% Precision Medicin
TLX DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
December 14, 2025 8:40 AM EST | Source: The Rosen Law Firm PA New York, New York--(Newsfile Corp. - December 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- newsfilecorp.com27
- fool.com.au4
- kalkinemedia.com3
- marketscreener.com3
- capitalbrief.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 49 articles, not a forecast.